Nephrogenic Ascites in End Stage Renal Disease: Pathophysiology, Clinical Features, and Management

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Background and hypothesis Nephrogenic ascites is an uncommon but clinically significant complication of advanced and end stage renal disease. It arises in the absence of hepatic, cardiac, malignant, or infectious causes, most often in patients established on long term dialysis but also, in a minority, before dialysis is initiated. Its pathophysiology differs substantially from cirrhotic ascites and involves a multifactorial interplay of haemodynamic, metabolic, and structural mechanisms. Understanding these mechanisms, and the strength of evidence supporting each, is essential for accurate diagnosis, appropriate management, and timely referral for transplantation. Methods This narrative review synthesises evidence from observational studies, case series, mechanistic studies, and review articles on the pathophysiology, differential diagnosis, and management of nephrogenic ascites in advanced and end stage renal disease. Records were screened independently by two reviewers, with disagreements resolved by a third. This is a narrative and not a systematic or scoping review. Results Nephrogenic ascites reflects multiple interacting pathways, including peripheral arterial vasodilation, chronic volume overload, elevated hepatic venous hydrostatic pressure, hypoalbuminaemia, impaired lymphatic drainage, and increased peritoneal membrane permeability. Uraemia associated endothelial dysfunction, systemic inflammation, uraemic toxin accumulation, immune complex deposition, haemosiderosis, prior peritoneal dialysis exposure, and endocrine disturbances may further amplify capillary permeability and disrupt peritoneal barrier integrity. Supporting evidence varies markedly across these mechanisms: only volume overload and impaired peritoneal drainage have been observed directly in affected patients, while hypoalbuminaemia, membrane permeability, and the microvascular and inflammatory pathways rest on evidence from dialysis populations or on extrapolation from broader chronic kidney disease literature. The condition carries a poor prognosis, and management is largely supportive. Kidney transplantation is the only definitive treatment, although comorbidity frequently limits eligibility. Conclusions Nephrogenic ascites is a refractory and morbid complication of advanced and end stage renal disease with limited therapeutic options. Dialysis dependence is its typical clinical context rather than an absolute diagnostic requirement. Accurate diagnosis requires systematic exclusion of alternative causes and cautious interpretation of the serum ascites albumin gradient. Future work should prioritise disease specific cohorts, patient reported outcomes, and comparative evaluation of treatment options.